

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 62264

Manuscript Type: CASE REPORT

S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report

STEM chemotherapy for NECB

Abstract

BACKGROUND

Neuroendocrine carcinoma of the breast (NECB) is a rare type of malignant tumour. Due to the rarity of NECB, the relevant literature mostly comprises case reports. Available data on treatment options for NECB are very limited

CASE SUMMARY

Match Overview

1	Internet 41 words crawled on 11-Apr-2020 www.mdpi.com	2%
2	Internet 41 words crawled on 05-Mar-2021 www.wjgnet.com	2%
3	Crossref 34 words Fernando Collado-Mesa , Jose M. Net , Geetika A. Klevos , Monica M. Yepes . "Primary neuroendocrine carcinoma of the breast: A case report"	1%
4	Internet 16 words crawled on 15-Apr-2021 clinicaltrials.gov	1%
5	Crossref 14 words Anna Koumariou , Gregory Kaltsas , Matthew H. Kulke , Kjell Oberg et al. "Temozolomide in Advanced Neuroendocrine Carcinoma of the Pancreas: A Case Report"	1%
6	Crossref Posted Content 14 words Özlem Özdemir , Baha Zengel , Yaşar Yıldız , Seray Saray et al. "Neuroendocrine Differentiated Breast Cancer Cases: A Case Report"	1%
7	Crossref 13 words Lena Marinova , Doroteya Malinova , Snezhinka Vicheva . "Primary Neuroendocrine Carcinoma of the Breast: Histopathological and Immunohistochemical Findings"	1%
8	Internet 13 words crawled on 21-Aug-2020	1%

S-1 plus temozolomide as an effective second-line treatment for ad



ALL

IMAGES

VIDEOS

10,400 Results

Any time ▾

Second-line treatment in patients with advanced extra ...

<https://journals.sagepub.com/doi/10.1177/1758835920915299>

Second-line therapy for patients with advanced EP-PD-NEC had limited efficacy in this meta-analysis, and a high Ki-67 was associated with treatment outcomes, as reported previously. 9,42 Indeed, the...

Cited by: 1

Author: Mairéad G McNamara, Melissa Frizziero,...

Publish Year: 2020

Successful treatment with temozolomide in an elderly ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320007>

There have been few reported cases of pulmonary large-cell neuroendocrine tumor accompanied by abdominal lymph node metastasis. The treatment of temozolomide (TMZ) in advanced stage...

Author: Juan Wei, Xiao Fang Dong, Zu Liang ...

Publish Year: 2018

PEOPLE ALSO ASK

Is it safe to take temozolomide with capecitabine? ▾

Can chemo prolong neuroendocrine tumors? ▾

When was the first classification of neuroendrine Tumors published? ▾

Is there a treatment for metastatic neuroendocrine tumor? ▾

Feedback

(PDF) Temozolomide as Second or Third Line Treatment of ...

<https://www.researchgate.net/publication/230843763...>

Temozolomide is commonly used in the second-line setting. Temozolomide was given with or without capecitabine and bevacizumab as second-line treatment after cisplatin-based chemotherapy i...

(PDF) Second-line treatment in patients with advanced ...

<https://www.researchgate.net/publication/340955962...>

Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis April 2020 Therapeutic Advanc...

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

11,200 Results

Any time ▾

[Metronomic temozolomide as second line treatment for ...](#)

europepmc.org/articles/PMC4855772 ▾

May 03, 2016 · Few prospective studies that investigate a **second line chemotherapy** in **neuroendocrine tumors** are available. In 2011 Welin et al. showed that **Temozolomide** may be an active, well tolerated, **second-line chemotherapy** regimen for NEC patients (mainly gastrointestinal) who have progressed after first-line **chemotherapy**. It seems to be effective also in lung **carcinoid**.

Cited by: 11

Author: C. De Divitiis, C. von Arx, A. M. Grimaldi, D. ...

Publish Year: 2016

[\(PDF\) Temozolomide as Second or Third Line Treatment of ...](#)

<https://www.researchgate.net/publication/230843763...>

There are, however, no published studies concerning **second-line treatment of the disease**. **Temozolomide** has shown clinical effect in well-differentiated endocrine carcinomas.

[Second-line treatment in patients with advanced extra ...](#)

<https://journals.sagepub.com/doi/10.1177/1758835920915299>

Apr 27, 2020 · **Second-line** therapy for patients with advanced EP-PD-NEC had limited efficacy in this meta-analysis, and a high Ki-67 was associated with **treatment** outcomes, as reported previously. 9,42 Indeed, the relevance of the proliferation marker Ki-67 in **neuroendocrine** tumours has long been reflected in the classification system, 43 and is also known to ...

Cited by: 2

Author: Mairéad G McNamara, Melissa Frizziero, Ti...

Publish Year: 2020

Estimated Reading Time: 9 mins

[Phase II study of temozolomide monotherapy in patients ...](#)

<https://europepmc.org/article/PMC/PMC8088944> ▾

Mar 12, 2021 · Extrapulmonary **neuroendocrine carcinoma** (EPNEC) is a lethal disease with a poor prognosis. Platinum-based chemotherapy is used as the standard first-line **treatment** for unresectable EPNEC. Several retrospective studies have reported the results of the utilization of **temozolomide** (TMZ) as a drug for the **second-line treatment** for EPNEC.

Cited by: 1

Author: Noritoshi Kobayashi, Yuma Takeda, Naoki ...

Publish Year: 2021

[\[PDF\] Neuroendocrine Carcinoma of the Stomach: A Response to ...](#)

<https://www.integ-jet-go.in/article/internalmedicine/57/5/57-0260-17/.pdf/ober/en>



ALL

IMAGES

VIDEOS

122,000 Results

Any time ▼

Metronomic temozolomide as second line treatment for ...

europepmc.org/articles/PMC4855772 ▼

May 03, 2016 · Few prospective studies that investigate a **second line chemotherapy** in **neuroendocrine tumors** are available. In 2011 Welin et al. showed that **Temozolomide** may be an active, well tolerated, **second-line chemotherapy** regimen for NEC patients (mainly gastrointestinal) who have progressed after first-line **chemotherapy**. It seems to be effective also in lung **carcinoid**.

Cited by: 11

Author: C. De Divitiis, C. von Arx, A. M. Grimaldi, D. ...

Publish Year: 2016

(PDF) Temozolomide as Second or Third Line Treatment of ...

<https://www.researchgate.net/publication/230843763...>

There are, however, no published studies concerning **second-line treatment of the disease**. **Temozolomide** has shown clinical effect in well-differentiated endocrine carcinomas.

Temozolomide as Second or Third Line Treatment of Patients ...

<https://www.hindawi.com/journals/tswj/2012/170496> ▼**Abstract**

Introduction

Material and Methods

Results

Discussion

Background. Knowledge of the clinical efficacy in recurrent **neuroendocrine carcinomas** is sparse. Treatment with **temozolomide** alone or in combination with capecitabine and bevacizumab has recently shown promising results. Patients and Methods. Analysis of consecutive patients with **neuroendocrine carcinomas** (Ki-67 proliferation index >20%) and performance status 0–2 treated with **temozolomide** 200 mg (qam orally days 1–5 every 28 days after at least one previous platinum-containing chemotherapy regimen).